이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

심혈관 자기공명(CMR) 영상의 기술 및 중개 개발

2026년 10월 2일 업데이트: National Heart, Lung, and Blood Institute (NHLBI)

심혈관 MRI(CMR)의 기술 및 중개 개발

Background:

Magnetic resonance imaging (MRI) is an important non-invasive tool to study and diagnose cardiovascular disease. MRI scanners use strong magnetic fields and radio waves to create pictures of body organs. Researchers want to find better MRI methods and new ways of imaging cardiovascular disease and better understand normal and abnormal cardiovascular and brain function. Researchers are also interested in seeing if gadolinium, the commonly used MRI contrast agent, stays in the body long after the MRI was performed.

Objectives:

To develop new methods for imaging the heart and other organs of the body.

To describe cardiovascular diseases using newer MRI methods

To look at the relationship between cardiovascular disease and cardiovascular risk factors and other organ systems

To look for gadolinium deposits in the brain from prior exams.

Eligibility:

Healthy people and people with known or suspected cardiovascular disease ages 7 and older may be eligible for this study.

Researchers may be particularly interested in those who:

  • Have suspected or known cardiovascular disease
  • Were previously exposed to a gadolinium-based contrast agent,
  • Need to have a heart MRI scheduled
  • Need a test of the heart or other body part or will be undergoing a future cardiac catheterization

Design:

There are multiple arms to the study with optional components; therefore, there are multiple variations as to what an individual participant s experience may involve.

Participants will have an MRI scan lasting up to 2 hours. The scanner is a large hollow tube. During the scan, there may be loud knocking and buzzing sounds caused by the scanner. Participants will lie on a table that slides in and out of the tube. Their vital signs may be monitored.

Participants may have a test of heart electrical activity using wires connected to pads on the skin.

Participants may have blood drawn.

Participants may be injected with an MRI contrast agent through a plastic tube inserted in the arm.

연구 개요

상세 설명

The purpose of this protocol is to develop and test new MRI techniques applicable to patients undergoing cardiovascular evaluation with the ultimate goal of translating the technical advances into improving clinical diagnosis and management of patients undergoing cardiovascular evaluation. Patients undergoing cardiovascular evaluation and healthy volunteers will be scanned under the protocol. We will evaluate new developments in non-contrast and contrast MRI of the heart and blood vessels and novel postprocessing methods.

The use of the newer sequences will be used to improve clinical imaging workflow and disease diagnosis. We hope to use this protocol to clearly describe cardiovascular disease and associated problems using novel MRI methods and follow certain subsets of patients with disease as part of a natural history process. Inter-related physiologic systems may be phenotyped by MRI with characterization of disease associations between different organ systems.

Additionally, information regarding gadolinium deposition of the brain will be gathered. The literature regarding deposition of gadolinium in the brain has a large void regarding information of prevalence of the phenomenon in healthy subjects. The National Institutes of Health has a large healthy subject pool who have participated in gadolinium contrast MRI studies. This pool of healthy subjects is not easily available at most clinical MRI centers, and thus, we are uniquely well-situated to be able to answer this outstanding question.

For all objectives, MRI studies will be conducted in the NIH MRI systems located at the NIH Clinical Center in Bethesda, Maryland. These procedures may involve the intravenous administration of commercially available MR contrast media and exercise or pharmacologic stress testing. Results will be used to evaluate the performance of various research pulse sequences, gradient coils, and radiofrequency receiver coils on human subjects and will provide essential ground work for specific patient protocols, both diagnostic and therapeutic.

연구 유형

관찰

등록 (추정된)

5000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: W. Patricia Bandettini, M.D.
  • 전화번호: (301) 451-3128
  • 이메일: ingkanisorn@nih.gov

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Institutes of Health Clinical Center
        • 연락하다:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 전화번호: TTY8664111010 800-411-1222
          • 이메일: prpl@cc.nih.gov

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

7년 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Primary care clinic

설명

  • INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:
  • Age >= 7 years
  • Able to follow instructions and lie still in the MRI scanner
  • Currently without known Cardiovascular disease
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures and available for scheduled study events

EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Important past or chronic medical illness such as major cardiovascular conditions like myocardial infarction, congenital heart disease, and known cardiomyopathy

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • eGFR < 60 mL/min/1.73m^2 using the 2021 CKD-EPI equation or equivalent (using the CRIScalculated eGFR to define the threshold) and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents

  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will under serum or urine pregnancy testing within 7 days of the day prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • If receiving contrast, breast feeding women (unless subject is willing to discard breast milk for 24 hours) are excluded

  • Healthy volunteer children will not have contrast

  • In a year's time, healthy volunteers are not restricted as to the number of non-contrast MRI examinations they undergo, but they may not undergo more than two examinations involving gadolinium-based contrast agents (GBCA) and those exposures will be at least 18 hours (12 half-lives) apart.

INCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED WITH HEART DISEASE:

  • Age >= 7 years
  • Subjects with known or suspected cardiovascular disease
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events

EXCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED HEART DISEASE:

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing 7 days prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • Breast feeding (unless subject is willing to discard breast milk for 24 hours if receiving contrast)

  • eGFR < 30 mL/min/1.73m^2 using the 2021 CKD-EPI equation or Community Practice Standard for Pediatric case or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents

  • Cardiorespiratory instability as determined by the enrolling clinician

INCLUSION CRITERIA FOR SUBJECTS WITH NON-CARDIAC DISEASE:

  • Age >= 7 years
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events
  • Known or suspected brain, hematology, oncology, endocrine, pulmonary, or other non-cardiac disease.

EXCLUSION CRITERIA FOR SUBJECTS WITH NON- CARDIAC DISEASE:

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate screening form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing on the day of the examination. In addition, the subject will be asked if she may be pregnant prior to the

performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • Breast feeding in those subjects receiving contrast (unless subject is willing to discard breast milk for 24 hours
  • eGFR < 30 mL/min/1.73m^2 using the 2021 CKD-EPI equation or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents
  • Cardiorespiratory instability or as determined by the enrolling clinician

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Assessing Gadolinium deposition within the brain in healthy and patient subjects

Both healthy subjects and patient subjects who have previously undergone MRI and received gadolinium.

Child Patient or Healthy Child

Healthy children will be used as controls for children with cardiac disease. Child patient will undergo MRI scans.

Healthy Volunteers

Subjects may be used to test image quality or functionality of MRI sequences; subjects may also be used as controls for adults with cardiac and non-cardiac disease.

Research Patients Cardiac and Non Cardiac

Adults with risk factors for cardiac disease or suspected or known cardiac disease

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Translational development of MRI sequences
기간: on going

Possible comparison to other studies that subjects may have undergone. Descriptive MRI catalogue of multiple cardiovascular processes Follow-up of outcomes subsequent to the MRI scan in select subject groups Follow-up of changes in diagnosis following the MRI scan in select subject groups

on going
Technical development of MRI sequences
기간: on going

Possible assessments include structure depictions, heart chamber volumes, blood flow velocity, image quality scores, pixelwise and segmental summary scores of parametric maps in the heart. Anatomical imaging may be assessed for non- cardiac applications. Contrast- to-noise, and signal-to-noise measurements may be performed. For novel sequences, comparisons to standard product sequences may be performed.

on going
Evaluating the correlation
기간: on going

Measurements of cardiac chamber size and function, vascular reactivity and perfusion are among the parameters that may be followed with comparison to standard biomarkers of disease and clinical manifestations of disease. Neurologic vascular reactivity, blood volume, resting state connectivity, BOLD signal changes may be compared among healthy subjects, asymptomatic subjects with risk factors, and subjects with disease.

on going
Assesment of Gad deposition in the brain
기간: on going

Assessment of non-contrast MRI findings that are consistent with gadolinium deposition.

on going

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: W. Patricia Bandettini, M.D., National Heart, Lung, and Blood Institute (NHLBI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 7월 12일

기본 완료 (추정된)

2028년 4월 1일

연구 완료 (추정된)

2028년 4월 1일

연구 등록 날짜

최초 제출

2018년 7월 3일

QC 기준을 충족하는 최초 제출

2018년 7월 7일

처음 게시됨 (실제)

2018년 7월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 2일

마지막으로 확인됨

2026년 9월 29일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

The study team will make a decision on this matter.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다